Organisation paid for research Program year 2025 Source: CMS Open Payments

CBH Health, LLC

Neither a doctor nor a teaching hospital

Research payments

$3,288,560

54 payments

Through program year 2025, CBH Health, LLC is reported as receiving $3,288,560 in research payments, across 54 payments.

By program year

4 rows
Year Kind Amount Payments
2025 Research $627,196 8
2024 Research $703,688 6
2021 Research $87,112 3
2020 Research $1,870,564 37

Breakdown

Who paid Research payments · program years 2020–2025
  1. Sunovion Pharmaceuticals Inc. $1,957,676 40 payments
  2. E.R. Squibb & Sons, L.L.C. $1,330,884 14 payments
Studies the money was for Research payments · program years 2020–2025
  1. A Clinical Trial to Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia $1,743,799 21 payments
  2. An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in De Novo Subjects With DSM-5 Schizophrenia $619,135 3 payments
  3. An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia $448,555 3 payments
  4. A Clinical Study to Evaluate the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia $198,265 18 payments
  5. A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia (ARISE) $134,481 1 payment
  6. Phase III Efficacy and Safety of KarXT in Adjuct Schiz (ARISE 1) $63,550 1 payment
  7. A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder $22,700 1 payment
  8. Phase III OLE of KarXT in Adjuct Schiz (ARISE 2) - An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia $19,329 1 payment
  9. Study name not reported $15,612 1 payment
  10. A Phase 3, Open-label Extension Study to Assess the Long-term Safety of KarXT for the Treatment of Mania or Mania with Mixed Features in Bipolar-I Disorder $15,200 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record